Skip to content

R&D at other companies

NeoGenomics logo
NeoGenomicsNEO
$9.53M-6.4%
Illumina logo
IlluminaILMN
$240M-4.8%
Veracyte logo
VeracyteVCYT
$27.1M+52.9%
Guardant Health logo
Guardant HealthGH
$91.04M+2.8%
Natera, Inc. logo
Natera, Inc.NTRA
$210.7M+63.2%
GeneDx Holdings logo
GeneDx HoldingsWGS
$19.8M+57.5%

Other financials

Income statement

See full
Revenue$15.5M-24.9%
Gross profit$281.0K-96.1%
Operating income-$32.2M-81.7%
Net income-$30.0M-90.7%
EPS (diluted)-$0.29-61.1%

Balance sheet

See full
Cash & equivalents$73.6M+3.7%
Total debt$39.0M-6.2%
Total equity$254.8M+22.9%
Total assets$325.4M+19.1%

Cash flow

See full
Operating cash flow-$22.5M-25.1%
CapEx$3.2M+27.1%
Free cash flow-$25.7M-25.4%

Valuation

See full
Market cap$1.19B+110%
Enterprise value$1.16B+115%
P/S18.4×+11.8×

Profitability

See full
Gross margin13.7%-19.6pp
Operating margin-158.9%-5,457pp
Net margin-148.1%+154pp
FCF margin-131.2%-453pp

Returns & leverage

See full
Return on equity-41.4%-6.7pp
Debt / equity0.2×0.0×
Current ratio6.6×-0.3×

Where this comes from

Reported directly by Personalis, Inc. in its filing.

Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.

The official record: Personalis, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Personalis, Inc.'s r&d.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Personalis, Inc.'s R&D?
Personalis, Inc. (PSNL) reported R&D of $14.54M in Q1 2026.
How has Personalis, Inc.'s R&D changed year-over-year?
Personalis, Inc.'s R&D increased by 15.0% year-over-year, from $12.64M to $14.54M.
What is the long-term trend for Personalis, Inc.'s R&D?
Over 4 years (2021 to 2025), Personalis, Inc.'s R&D has grown at a 0.5% compound annual growth rate (CAGR), from $49.31M to $50.26M.
What does R&D mean?
Costs of research activities to discover new knowledge and development activities to translate research into new or improved products, services, processes, or technologies.